Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption

• Published in: Viruses Vol. 13; no. 2; p. 335
• Main Authors: Wang, Xiaolei, Xu, Huanbin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.02.2021; MDPI
• Subjects: Animals; Anti-Retroviral Agents - therapeutic use; antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; Bone marrow; Cell division; cell-associated viral reservoir; Deoxyribonucleic acid; DNA; DNA, Viral - genetics; DNA, Viral - metabolism; Genomes; HIV; HIV infections; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - genetics; Human immunodeficiency virus; Humans; Immunology; Infections; Lymphatic system; Lymphocytes; patients; proviral reservoir; Proviruses; Proviruses - genetics; Proviruses - physiology; Remission; Replication; Review; risk; SIV; therapeutics; vaccines; Viral Load; Viremia; Virus Latency; Viruses; SIV; cell-associated viral reservoir; proviral reservoir; HIV

Antiretroviral therapy (ART) has dramatically suppressed human immunodeficiency virus (HIV) replication and become undetectable viremia. However, a small number of residual replication-competent HIV proviruses can still persist in a latent state even with lifelong ART, fueling viral rebound in HIV-i...